CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	FlexBiosys, Inc.	FlexBiosys, Inc. Common Stock	FlexBiosys, Inc. Additional Paid-In Capital
Translation adjustment	$ (2,795)			$ (2,795)
Balance at Dec. 31, 2022	1,910,700	$ 556	$ 1,547,266	(34,394)	$ 397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income	48,893				48,893
Conversion of debt	(3)		(3)
Conversion of debt (in shares)		6
Exercise of stock options and vesting of stock units	62	$ 2	60
Exercise of stock options and vesting of stock units (in shares)		176,394
Tax withholding on vesting of restricted stock units	(11,140)	$ (1)	(11,139)
Tax withholding on vesting of restricted stock units (in shares)		(63,238)
Issuance of common stock pursuant to the acquisition						$ 5,243	$ 0	$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229	$ 0	7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	12,737		12,737
Balance at Jun. 30, 2023	1,970,926	$ 557	1,561,393	(37,189)	446,165
Ending Balance (in shares) at Jun. 30, 2023		55,744,896
Balance at Mar. 31, 2023	1,940,492	$ 556	1,544,956	(31,121)	426,101
Beginning Balance (in shares) at Mar. 31, 2023		55,644,301
Net income	20,064				20,064
Conversion of debt	(3)	$ 0	(3)
Conversion of debt (in shares)		6
Exercise of stock options and vesting of stock units	33	$ 1	32
Exercise of stock options and vesting of stock units (in shares)		36,184
Tax withholding on vesting of restricted stock units	(1,547)	$ 0	(1,547)
Tax withholding on vesting of restricted stock units (in shares)		(9,631)
Issuance of common stock pursuant to the acquisition						$ 5,243	$ 0	$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229	$ 0	7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	5,483		5,483
Balance at Jun. 30, 2023	1,970,926	$ 557	1,561,393	(37,189)	446,165
Ending Balance (in shares) at Jun. 30, 2023		55,744,896
Translation adjustment	(6,068)			(6,068)
Balance at Dec. 31, 2023	1,971,203	$ 558	1,569,227	(37,431)	438,849
Beginning Balance (in shares) at Dec. 31, 2023		55,766,078
Net income	5,415				5,415
Conversion of debt	(107)	$ 0	(107)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	1,788	$ 2	1,786
Exercise of stock options and vesting of stock units (in shares)		152,481
Tax withholding on vesting of restricted stock units	(8,857)	$ (1)	(8,856)
Tax withholding on vesting of restricted stock units (in shares)		(47,109)
Issuance of common stock pursuant to contingent consideration earnout payment	5,742	$ 0	5,742
Issuance of common stock pursuant to contingent consideration earnout payments		31,408
Stock-based compensation expense	17,990		17,990
Balance at Jun. 30, 2024	1,986,362	$ 559	1,585,782	(44,243)	444,264
Ending Balance (in shares) at Jun. 30, 2024		55,902,860
Translation adjustment	(1,531)			(1,531)
Balance at Mar. 31, 2024	1,970,601	$ 559	1,571,811	(42,712)	440,943
Beginning Balance (in shares) at Mar. 31, 2024		55,841,318
Net income	3,321				3,321
Conversion of debt	(53)	$ 0	(53)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	842	$ 0	842
Exercise of stock options and vesting of stock units (in shares)		40,560
Tax withholding on vesting of restricted stock units	(1,234)	$ 0	(1,234)
Tax withholding on vesting of restricted stock units (in shares)		(7,658)
Issuance of common stock pursuant to contingent consideration earnout payment	5,202	$ 0	5,202
Issuance of common stock pursuant to contingent consideration earnout payments		28,638
Stock-based compensation expense	9,214		9,214
Balance at Jun. 30, 2024	1,986,362	$ 559	$ 1,585,782	(44,243)	$ 444,264
Ending Balance (in shares) at Jun. 30, 2024		55,902,860
Translation adjustment	$ (6,812)			$ (6,812)